Maiwald blog articles
Implementation of the Pharmaceutical Strategy for Europe and the Intellectual Property Action Plan – Part 2
In addition to the Pharmaceutical strategy for Europe[1], the European Commission adopted a new Action Plan for Intellectual Prop...
Continue reading
Implementation of the Pharmaceutical Strategy for Europe and the Intellectual Property Action Plan – Part 1
Back in November 2020, the European Commission proposed a new Pharmaceutical Strategy for Europe which aims at ensuring the quality and safety of medicines while strengthening...
Continue reading
Revision of G3/04? – Discussion on the continuation of the appeal by intervener
In opposition appeal proceedings "T1286/23.3.2.04", Board 3.2.4 intends to deviate from decision G 3/04 and thus raises the prospect of a corresponding question being referred...
Continue reading
The road to G1/23 “solar cell” – Determining the fate of commercial polymer products as prior art
By interlocutory decision of 27 June 2023 in case T 438/19
Continue reading
Dr. Michaela Weigel-Krusemarck on current developments in formal priority law
In the course of our regular internal attorney seminar,
Continue reading
One year Unitary Patent and Unified Patent Court in facts and figures
We are already one year into the new European patent and court system – a year of eagerly watching and waiting to see how the Unitary Patent (UP) and the Unified Pa...
Continue reading
